medwireNews: The EMA has adopted a positive opinion for use of the PARP inhibitor rucaparib in patients with progressive or relapsed ovarian cancer.
The Committee for Medicinal Products for Human Use has recommended that rucaparib be given as a monotherapy against BRCA-mutated, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Specifically, the agent may be given to patients with platinum-sensitive, relapsed or progressive disease who have previously received two or more lines of platinum-based chemotherapy and are unable to tolerate further treatment.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group